The Meningitis Flag

Created in collaboration with three para-athletes, Ellie Challis, Théo Curin, Davide Morana and several members of the Meningitis Research Foundation / Confederation of Meningitis Organisations, the Meningitis Flag aims to raise public awareness of a disease that remains one of the world’s largest infectious disease killers.

Women at Sanofi - Cristina

Meet Cristina Zamora, our North America R&D Operations Project Lead and one of the many inspiring scientists that are helping to empower the next generation of female leaders in healthcare and beyond.

200 days to go until the Paris 2024 Paralympic Games

As para-athletes are gearing up to fly their country’s flag, a new flag will be flying: the Meningitis Flag to unite the world in the fight against meningitis. 

Virus VS Bacteria

They're part of your life, but do you really know them? Our scientists explain the main differences between a virus and a bacteria. 

Our Consumer Healthcare’s B Corp Journey

Becoming B Corp certified in Sanofi Consumer Healthcare North America, Germany, Italy and Hispanic Latin America means we’re part of a global community that’s transforming business into a force for good.

Sleeping Sickness: Leaving No One Behind

A neglected tropical disease, sleeping sickness is usually fatal without treatment. Patients infected with the more acute T.b rhodesiense variant of the disease have sadly seen little innovation in treatment options, but hope is on the horizon. For these patients, we see the potential of the first oral treatment for this variant of the disease, supporting the goal of elimination of sleeping sickness in humans by 2030.

Recognizing the people who taught us to never settle

Diagnosed with traverse myelitis at the age of 13, Lauren put her passion for sports on hold. Her mum reignited it. Lauren, today a double Paralympic gold medalist rower, is heading for the Paris 2024 Paralympic Games, with her mum by her side.

Sanofi Today

Your Health

February 7, 2024

#NoJargon: Dive into the world of science

Our latest news

February 24, 2024
Press Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria
February 24, 2024
Media Update: Dupixent® continues scientific leadership with late-breaking results showing reduced airway inflammation and mucus plugging in adults with uncontrolled moderate-to-severe asthma
February 23, 2024
Press Release: Filing of the 2023 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report
February 23, 2024
Press Release: Dupixent® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inflammation

Explore More

Diversity, Equity, and Inclusion Report

In the first full year of our new People and Culture strategy, Diversity, Equity, and Inclusion took center stage. This report celebrates the tangible progress we’ve made towards reflecting diversity in our leadership, unleashing the full potential of our people, and achieving impact in and beyond the workplace.

Our Legacy

Our company of today is built on a heritage of turning the impossible into the possible.

Our Integrated Report 2022

Discover how we’re making the impossible possible to improve people's lives everywhere.

Explore Career Opportunities

You'll be surprised what you can achieve at Sanofi. Discover your future here.